Yes, so long as the patient was able to tolerate the treatment and kept to strict dose intervals, then results looked pretty good (very small sample size - 4). The data presented is a little unclear, but shows promise.
The issue with tolerability lead them to develop a gel formulation for future burns trials, which has been used under the SAS with great results so far (the cases they've chosen to present anyway).
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion, page-26
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
-0.020(4.00%) |
Mkt cap ! $111.2M | |||
| Open | High | Low | Value | Volume |
| 50.0¢ | 50.0¢ | 47.5¢ | $60.72K | 126.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 764 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 17972 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| RCE (ASX) Chart |